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The impact of P-glycoprotein (MDR1, ABCB1) on drug disposition in the lungs as well as its presence and
activity in in vitro respiratory drug absorption models remain controversial to date. Hence, we character-
ised MDR1 expression and the bidirectional transport of the common MDR1 probe 3H-digoxin in air–
liquid interfaced (ALI) layers of normal human bronchial epithelial (NHBE) cells and of the Calu-3
bronchial epithelial cell line at different passage numbers. Madin–Darby Canine Kidney (MDCKII) cells
transfected with the human MDR1 were used as positive controls. 3H-digoxin efﬂux ratio (ER) was low
and highly variable in NHBE layers. In contrast, ER = 11.4 or 3.0 were measured in Calu-3 layers at a
low or high passage number, respectively. These were, however, in contradiction with increased MDR1
protein levels observed upon passaging. Furthermore, ATP depletion and the two MDR1 inhibitory anti-
bodies MRK16 and UIC2 had no or only a marginal impact on 3H-digoxin net secretory transport in the
cell line. Our data do not support an exclusive role of MDR1 in 3H-digoxin apparent efﬂux in ALI Calu-
3 layers and suggest the participation of an ATP-independent carrier. Identiﬁcation of this transporter
might provide a better understanding of drug distribution in the lungs.
 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
Compared to the gastro-intestinal tract, kidney, liver or brain,
the expression and functionality of drug transporters remain
poorly characterised in the lung, which renders pulmonary drug
absorption data challenging to interpret [1,2]. Since the epithelium
is the major permeability barrier in the lung, in vitro respiratory
epithelial cell culture models have been employed to enhance
understanding of the role of active transport mechanisms in the
disposition of inhaled drugs [1,3]. In absence of a convenient and
truly representative model of the alveolar epithelium, bronchial
systems have been favoured [3,4]. Among these, the human bron-
chial cell line Calu-3 and normal human bronchial epithelial(NHBE) cells are gaining in popularity due to their capacity to de-
velop polarised cell layers morphologically similar to the native
epithelium and suitability for permeability measurements when
cultured at an air–liquid interface (ALI) [4–6]. However, although
the presence of active drug transport mechanisms has been con-
ﬁrmed in Calu-3 and NHBE layers [1,6–9], an overview of the range
of transporters being expressed and functional in these models is
still lacking.
P-glycoprotein/multidrug resistance protein 1 (P-gp/MDR1) is a
member of the ATP-binding cassette (ABC) efﬂux transporter fam-
ily and plays a major role in drug–drug interactions [10], limitation
of oral drug absorption and poor drug penetration in the central
nervous system [11]. As it has been reported several drugs admin-
istered by the pulmonary route might be MDR1 substrates [1], tar-
geting the transporter present in the epithelium has been
envisaged as a strategy to increase the residence time of inhaled
drugs in the lung tissue. Consequently, MDR1 is by far the most
extensively studied drug transporter in the lung [1]. Although
weakly expressed in the lung as compared to other major organs
[12], the presence of the MDR1 protein has been demonstrated
in the bronchial epithelium [1]. However, its actual impact on
the pulmonary absorption of established substrates is a matter of
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functionality of MDR1 in bronchial epithelial cell culture models
are conﬂicting [1]. Passage number and time in culture have re-
cently been shown to impact on MDR1 expression or activity in
ALI bronchial epithelial layers [6,13,14], which may partly explain
discrepancies between studies.
Identifying the transporter protein involved in carrier-mediated
drug trafﬁcking is highly challenging in biological systems express-
ing multiple transporters with broad and overlapping substrate
speciﬁcities. For instance, the cardiac glycoside digoxin has been
well characterised as an MDR1 substrate and is largely used for
evaluating the risk of drug–drug interactions with new chemical
entities consequent to their modulation of MDR1 activity [15,16].
Accordingly, although not an inhaled drug, digoxin has been used
for probing MDR1 activity in bronchial cell culture models [13]
and in rodent lungs [13,17]. However, digoxin has also been de-
scribed as a substrate for carriers other than MDR1. These belong
to both families of ABC efﬂux pumps and organic anion transport-
ing polypeptide uptake transporters (OATP; gene symbol: SLCO),
namely MDR3 [18]; OATP1B3 [19] and OATP4C1 [20,21]. Con-
versely, more recent studies have shown OATP1B3, as well as OAT-
P1A2, OATP1B1 and OATP2B1, do not transport digoxin [22,23]. In
addition, it is now largely acknowledged that chemical inhibitors
commonly used in functional or mechanistic studies, including
those originally thought to be speciﬁc, actually interact with multi-
ple transporters [24,25].
In this context, our aim was to characterise the bidirectional
transport of digoxin in ALI bronchial epithelial cell layers in order
to evaluate the contribution of the MDR1 efﬂux pump and thus
the reliability of the drug as a MDR1 probe in such models. To as-
sist in the analysis of in vitro permeability data, the expression of a
range of transporter genes was initially proﬁled in the cell culture
models. After conﬁrmation of the presence of the MDR1 protein in
bronchial epithelial cell layers, the impact of a panel of chemical,
immunobiological and metabolic inhibitors on digoxin apparent
efﬂux was investigated in an attempt to identify the transporter in-
volved. Layers of Madin–Darby canine kidney epithelial (MDCKII)
cells transfected with the human MDR1 transporter and their wild
type counterparts were used for comparison throughout the study.2. Materials and methods
2.1. Cell culture
Unless otherwise stated, all reagents were purchased from Sig-
ma–Aldrich, UK. The human cancerous bronchial epithelial cell line
Calu-3 was obtained from the ATCC (Rockville, MD, USA) and used
at a ‘low’ (25–30) or ‘high’ (45–50) passage number. Cells were
maintained as previously described [13]. For experiments, they
were seeded at a density of 1  105 cells/cm2 on 12 well 0.4 lm
pore size polyester Transwell cell culture supports (Corning
Costar, High Wycombe, UK). Cells were raised to the air–liquid
interface (ALI) after 24 h and maintained on ﬁlters for 21 days prior
to experimentation.
Normal human bronchial epithelial (NHBE) cells (Lonza, Slough,
UK) were cultured using the Lonza proprietary B-ALI kit according
to the manufacturer’s instructions. Cells at passage number 2 were
seeded at a density of 1.5  105 cells/cm2 onto 0.33 cm2 polyester
Transwell cell culture supports (Corning Costar) pre-treated with
30 lg/ml rat tail type 1 collagen (Calbiochem, Nottingham, UK).
The medium was replaced on the following day, and after 72 h,
cells were raised to the ALI. The medium was thereafter changed
every 2–3 days, and cell layers were used after 21 days at the ALI.
The human cancerous colonic epithelial cell line Caco-2 and the
human embryonic kidney HEK293 cell line were obtained from theATCC. Wild type and MDR1 transfected Madin–Darby Canine Kid-
ney (MDCKII-WT and MDCKII-MDR1) cells were purchased from
the Netherlands Cancer Institute (NKI-AVL, Amsterdam, Nether-
lands). All cells were cultured in DMEM supplemented with 10%
% v/v foetal bovine serum, 100 IU/ml penicillin-100 lg/ml strepto-
mycin solution, 2 mM L-glutamine and 1% v/v non-essential amino
acids. Cells were seeded at a density of 2  105 cells/cm2 on 12 well
polyester Transwell cell culture supports and cultured under sub-
merged conditions for 5 (HEK293, MDCKII) or 21 (Caco-2) days.
2.2. Gene expression analysis
Calu-3 and NHBE cell layers were harvested from Transwell in-
serts on the same day as 3H-digoxin permeability experiments.
mRNA isolation and cDNA synthesis were performed as described
previously [26].
Manual TaqMan analysis of the ABCC7 and ABCC10-12 genes
was performed in triplicate in a 25 ll reaction mixture containing
30 ng cDNA, TaqMan Universal PCR Master Mix (containing Amp-
liTaq Gold DNA polymerase, dNTPs with dUTP, passive reference
and optimised buffer) and Assay-on-demand™ gene expression as-
say mix (containing 18 lM random hexamer primers). All other
genes investigated were analysed via automated Taqman PCR
low density arrays using custom designed 384-well cards as de-
scribed previously [26]. Ampliﬁcation curves were analysed using
the SDS2.1 software (Applied Biosystems, Foster City, CA) and
thresholds for generation of CT data were calculated automatically
by the software. Target genes were compared with the two house-
keeping genes RPLP0 (Large Ribosomal Protein) and MVP (Major
Vault Protein) DCT and assigned arbitrary categories for relative
gene expression levels based on the 2DCT value, i.e. relative expres-
sion levels >0.5 were considered as ‘high’ (+++), 0.02–0.5 as ‘mod-
erate’ (++), 0.001–0.02 as ‘low’ (+) and <0.001 as ‘negligible’ ().
2.3. Western blotting
Cells were detached from the surface of the ﬁlters/ﬂasks by the
addition of 500 ll non-enzymatic cell dissociation buffer prepared
in HBSS without calcium and magnesium salts. Cells were counted
and resuspended in RIPA cell lysis buffer containing 1 ll of prote-
ase inhibitor cocktail set II per 200 ll (ratio of 20 million cells per
1 ml buffer solution) and agitated at 700 rpm at 4 C for 30 min.
Cell debris was pelleted at room temperature by centrifugation
at 12,000g for 20 min and the resulting supernatant decanted. Pro-
tein concentration was quantiﬁed using the RC DC™ protein assay
(BioRad, Hemel Hempstead, Hertfordshire).
Protein samples were resolved using 7% Tris–acrylamide gels.
Brieﬂy, 10 ll of cell lysate solution containing 20–30 lg of protein
was diluted 1:1 with reducing sample buffer. Samples were run
under denatured and reduced conditions alongside 5 ll precision
plus protein standards (BioRad, Hemel Hempstead, UK) and re-
solved at 0.04 amps in running buffer.
Transfer to a nitrocellulose membrane was conducted for
60 min at 100 V and at a temperature of 4 C. Proteins transferred
onto Western blots were visualised by staining with copper phtha-
locyanine 3,40,400,400 0-tetrasulphonic acid tetrasodium salt (CPTA).
Samples were probed for the presence of MDR1 protein using
5 lg/ml of the mouse anti P-glycoprotein C219 primary antibody
(Calbiochem, Nottingham, UK) for 16 h at 4 C. All steps were per-
formed using a chemiluminescence detection kit according to the
manufacturer’s instructions (Invitrogen, Paisley, UK).
2.4. Immunohistochemistry
Cell layers were probed for MDR1 protein expression on the
same day as functional experiments. Cell layers were rinsed twice
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15 min. Fixed cell layers were permeabilised using 0.1% v/v Triton
X-100 in PBS for 5 min and rinsed in PBS. Samples were blocked for
30 min with 1% w/v bovine serum albumin (BSA) in PBS to prevent
non-speciﬁc binding, followed by incubation with the primary
mouse anti-human MDR1 antibodies: 15 lg/ml MRK16 (Abnova,
Newmarket, UK) or 20 lg/ml UIC2 (Enzo Life Sciences, Exeter,
UK) in blocking solution for 60 min at 37 C. Cells were washed
in 1% w/v BSA in PBS to remove unbound primary antibody before
incubation with a solution of the secondary FITC-labelled goat anti-
mouse IgG (1:64) in PBS, for a further 30 min. Cell nuclei were
counter-stained with propidium iodide (PI) 1 lg/ml in PBS for
30 s. Inserts were washed with PBS before the ﬁlter was excised
and mounted on a slide using DABCO anti-fade mounting media.
Samples were imaged by a Meta 510 confocal microscope (Zeiss,
Welwyn Garden City, UK), excited at 485 nm and 543 nm wave-
lengths and emission observed at 519 nm and 617 nm for FITC
and PI, respectively. Z-stack reconstructions of samples were the
average of four images for every 0.5 lm slice through the sample.
2.5. Flow cytometry
On the day of 3H-digoxin transport studies, cells were detached
from Transwell inserts using trypsin and resuspended in 0.5% v/v
FBS in PBS. The cell suspension was adjusted to 1 million cells/ml
and 100 ll samples were transferred to clean ﬂow cytometry
tubes. Primary anti-MDR1 antibodies (either MRK16 (1 lg) or
UIC2 (0.2 lg)) were added and samples incubated at 37 C for
30 min. Cells were washed and pelleted in cold ‘stop solution’
(0.5% v/v FBS and 0.1% w/v sodium azide in PBS). The supernatant
was decanted, and cells were resuspended in 100 ll ‘stop solution’
containing FITC-labelled goat anti-mouse IgG (1:1000) and incu-
bated at 4 C for 30 min. After two PBS wash steps to remove any
unbound secondary antibody, samples were ﬁxed by the addition
of 500 ll ﬁxing solution (0.5% v/v formaldehyde in PBS) and stored
at 4 C in the dark for up to 1 week before analysis. An unstained
sample and the appropriate isotype controls were included in each
analysis to address autoﬂuorescence and non-speciﬁc binding,
respectively.
For data analysis, each sample population was gated to only in-
clude cells of interest based on either their forward scatter (cell
size) and/or side scatter (cell granularity) proﬁles. Dead cells were
identiﬁed from optimisation experiments with PI and excluded
from the analysis. A total of 30,000 events were collected for each
sample. Raw data were analysed using WinMDI 2.9 software (build
#2, 6-19-2000; Scripps Research Institute: http://facs.scripps.edu/
software.html) and the mean ﬂuorescence intensity (MFI) value
was determined as MFI = [MFI value for sample]  [MFI value for
isotype/unstained sample] for each marker.
The UIC2 shift assay was performed as described previously
[27]. Samples were treated as outlined above, but ﬁrst incubated
at room temperature for 10 min either alone in 0.5% v/v FBS in
PBS or in presence of the chemical inhibitors PSC833 (1 lM) or
MK571 (30 lM), before the addition of the UIC2 primary antibody
(2 lg/ml). The relative MFI was calculated as the ratio between the
MFI of the sample (treated with inhibitor) against the MFI of the
cells alone.
2.6. Transport studies
Permeability experiments were conducted using 25 nM 3H-di-
goxin (Perkin Elmer, Cambridge, UK) in 5 day (MDCKII cells) or
21 day (Calu-3 and NHBE cells) old cell layers in the apical to baso-
lateral (AB) and basolateral to apical (BA) directions in quadrupli-
cate. 14C-mannitol (6.55 lM, Perkin Elmer) was used in all
experiments as a marker of epithelial barrier integrity. Cell layerswere allowed to equilibrate at 37 C for 60 min in standard buffer
solution (SBS) comprising HBSS supplemented with 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 1% v/v
dimethyl sulfoxide (DMSO) in presence or absence of the inhibitors
PSC833 (1 lM), MK571 (30 lM) or sodium azide (15 mM). Trans-
epithelial electrical resistance (TEER) measurements were taken
using an EVOMmeter with chopstick electrodes (World Precision
Instruments, Stevenage, UK) and only bronchial epithelial cell lay-
ers with a TEER > 300X cm2 were accepted for experiments. Per-
meability studies were then carried out as previously detailed
[13] maintaining the concentration of substrate, paracellular mar-
ker and inhibitors constant throughout the experiments. Cells were
maintained at 37 C and rotated at 60 rpm on an orbital shaker
with the exception of temperature dependent studies where the
samples were maintained at 4 C. For biochemical inhibition as-
says, cell layers were ﬁrst incubated in SBS containing the mouse
anti-human MDR1 antibodies (20 lg/ml UIC2 or 15 lg/ml
MRK16) for 60 min at 37. This was then removed prior to conduct-
ing the transport experiments as outlined above. The TEER was
measured again at the end of the transport studies to verify the
integrity of the cell layers. All samples were mixed with 2 ml Opti-
Phase HiSafe 2 scintillation cocktail (Perkin Elmer, Cambridge, UK)
and counted using a Wallac 1490 liquid scintillation counter
(Wallac, Turku, Finland).
Apparent permeability coefﬁcients (Papp) were calculated using
the following equation: Papp ¼ dQ=dtAC0 where dQ/dt is the ﬂux of the
substrate across the cell layer, A is the surface area of the ﬁlter
and C0 is the initial concentration of the substrate in the donor
solution.
Cell layers with 14C-mannitol Papp values >1.5  106 cm/s were
excluded from the analysis. Efﬂux ratios were calculated as the ra-
tio of the secretory (BA)/absorptive (AB) apparent permeability
(Papp) values.2.7. ATP depletion assay
Calu-3 and MDCKII cell layers were incubated for 3 h in either
SBS alone or in SBS containing 15 mM sodium azide. No signiﬁcant
reduction in TEER values was observed at the end of the exposure
time. Cells were then assayed for ATP content using the ATP-lite
kit (Perkin Elmer) according to the manufacturer’s instructions
with minor amendments. In brief, cells were lysed using 50 ll cell
lysis buffer at room temperature on an orbital shaker set at
700 rpm. After 5 min, 100 ll luminescent substrate buffer was
added and samples were incubated for a further 5 min at
700 rpm. Samples were then transferred to a black 96 well plate,
dark adapted for 10 min and analysed for luminescence. ATP con-
tent was expressed as the average % relative to the control (SBS
alone; n = 3 layers).2.8. Statistics
Results for permeability data were expressed as mean ± stan-
dard deviation. Initial data sets with nP 5 were assessed for nor-
mality and the data were shown to ﬁt a normal (Gaussian)
distribution. Therefore, normality was assumed for all data sets
presented in this study. These were compared using a two-tailed,
unpaired Student’s t-test with Welch correction applied (to allow
for unequal variance between data sets). Statistical signiﬁcance
was evaluated at 99% (p < 0.01) and 95% (p < 0.05) conﬁdence
intervals. Data considered to be statistically signiﬁcantly different
from control conditions are represented with  or , respectively.
All statistical tests were performed using GraphPad InStat version
3.06.
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3.1. Transporter gene expression
Recently, the expression of a panel of drug transporters has
been mapped by semi-quantitative reverse transcriptase poly-
merase chain reaction in human airway epithelial cells grown
under submerged conditions on tissue culture plates [28]. Com-
paratively, a quantitative analysis of transporter expression in
respiratory cell culture absorption models is currently lacking,
whereas this would aid the interpretation of in vitro pulmonary
permeability data. Hence, we evaluated the expression of se-
lected drug transporter genes in 21 day old ALI Calu-3 layers
at a low (25–30) or high (45–50) passage number as well as
in NHBE layers grown in similar conditions for comparison. For
the majority of transporters investigated, transcript levels were
similar between NHBE and Calu-3 layers with no impact of the
cell line passage number (Table 1). When differences in trans-
porter expression were obtained between the in vitro models
investigated, these were restricted to one arbitrary category (as
deﬁned in the method section). This reveals that, despite being
of cancerous origin, Calu-3 layers appear to be a suitable
in vitro model in which to investigate broncho-epithelial drug
transporters. However, it is noteworthy that ABCB1 (MDR1)
expression levels were inconsistent between the three cell cul-
ture systems studied. Indeed, they were determined as negligible
in NHBE cells, low in Calu-3 cells at a high passage and moder-
ate in low passage Calu-3 layers (Table 1).Table 1
Gene expression of selected ABC and SLC transporters in human bronchial epithelial cell l
Gene Protein Calu-3 low passage Calu-3 high pass
MVP LRP ++ ++
RPLP0 RPLP0 +++ +++
ABCB1 MDR1 ++ +
ABCB4 MDR3  
ABCB11 BSEP + 
ABCC1 MRP1 ++ ++
ABCC2 MRP2 + +
ABCC3 MRP3 ++ ++
ABCC4 MRP4 + +
ABCC5 MRP5 ++ ++
ABCC6 MRP6 + +
ABCC10 MRP7 ++ ++
ABCC11 MRP8  
ABCC12 MRP9  
ABCC7 CFTR ++ ++
ABCG2 BCRP  
SLC15A1 PEPT1 + 
SLC15A2 PEPT2 + 
SLC22A1 OCT1 ++ +
SLC22A2 OCT2  
SLC22A3 OCT3 + +
SLC22A4 OCTN1  
SLC22A5 OCTN2 ++ +
SLC22A6 OAT1  
SLC22A7 OAT2  
SLC22A8 OAT3  
SLC22A9 OAT4  
SLCO1A2 OATP1A2  
SLCO1B1 OATP1B1  
SLCO1B3 OATP1B3 ++ ++
SLCO1C1 OATP1C1  
SLCO2B1 OATP2B1  
SLCO3A1 OATP3A1 ++ ++
SLCO4A1 OATP4A1 ++ ++
SLCO4C1 OATP4C1 ++ +
Signal intensity represented as:  (<0.001) ‘negligible expression’; + (0.001–0.02) ‘low
compared to the two house-keeping genes RPLP0 and MVP.3.2. MDR1 protein expression
Three different protein detection techniques and a panel of
MDR1 antibodies were employed to conﬁrm the presence of
MDR1 in bronchial in vitro permeability models.
Western blotting with the C219 antibody detected a protein
band at 170 kDa for the two positive controls Caco-2 and
MDCKII-MDR1 cells which was absent for the negative control cell
lines HEK293 and MDCKII-WT (Fig. 1). In comparison, protein
bands were observed at 150 kDa for all Calu-3 cell lysates and
were the strongest for cells at a high passage number cultured at
the ALI (Fig. 1).
The mouse anti-human MDR1 antibodies UIC2 and MRK16
were subsequently used for immunohistochemistry and ﬂow
cytometry. A positive immunohistochemical signal was obtained
with both antibodies on the apical membranes of all but HEK293
cell layers investigated (Fig. 2). This was however discontinuous
on NHBE and low passage Calu-3 layers (Fig. 2). Both MDCKII-WT
and MDCKII-MDR1 cell layers stained positively, possibly due to
the cross-reactivity of the antibodies with the canine mdr1 ex-
pressed in the cells [29]. Staining appeared nevertheless more in-
tense for the transfected cells.
Flow cytometry using the UIC2 antibody produced a low MFI
value of 1.3 with the negative control MDCKII-WT cells, whereas
the MDCKII-MDR1 positive cell control generated a MFI value of
7.5, demonstrating the UIC2 antibody reacts speciﬁcally with
MDR1. At low passage, 36% of Calu-3 cells were shown to express
the MDR1 transporter in comparison with 70% at a high passage,ayers.
age NHBE Assay ID Sequence accession ID
++ Hs00245438_m1 NM_017458
+++ Hs99999902_m1 NM_001002
 Hs00184500_m1 NM_000927
 Hs00240956_m1 NM_000443
+ Hs00184824_m1 NM_003742
++ Hs00219905_m1 NM_004996
+ Hs00166123_m1 NM_000392
++ Hs00358656_m1 NM_003786
+ Hs00195260_m1 NM_005845
++ Hs00194701_m1 NM_005688
 Hs00184566_m1 NM_001171
++ Hs00375701_m1 NM_033450
 Hs00261567_m1 NM_032583
 Hs00264354_m1 NM_033226
+ Hs00357011_m1 NM_000492
+ Hs00184979_m1 NM_004827
++ Hs00192639_m1 NM_005073
++ Hs00221539_m1 NM_021082
+ Hs00427550_m1 NM_153187
 Hs00533907_m1 NM_153191
++ Hs00222691_m1 NM_021977
 Hs00268200_m1 NM_003059
++ Hs00161895_m1 NM_003060
 Hs00537914_m1 NM_153276
 Hs00198527_m1 NM_153320
 Hs00188599_m1 NM_004254
 Hs00218486_m1 NM_018484
 Hs00366488_m1 NM_134431
 Hs00272374_m1 NM_006446
+ Hs00251986_m1 NM_019844
 Hs00213714_m1 NM_017435
 Hs00200670_m1 NM_007256
++ Hs00203184_m1 NM_013272
++ Hs00249583_m1 NM_016354
++ Hs00698884_m1 NM_180991
expression’, ++ (0.02–0.5) ‘moderate expression, +++ (>0.5) ‘high expression as
Fig. 1. Detection of MDR1 protein by Western blotting. (A) Calu-3 cell lysates at low and high passage cultured in ﬂasks for 7 days or on Transwell at the ALI for 14 or
21 days. Caco-2 cell lysate was used as a positive control. (B) MDCKII-MDR1, MDCKII-WT and HEK293 lysates from cells cultured in ﬂasks for 5 days. Samples were run
alongside molecular weight markers (MW) and a blank control (lysis and loading buffer solutions only).
Fig. 2. Confocal laser scanning micrographs of indirect immunoﬂuorescent staining for MDR1 in NHBE cell layers and Calu-3 cells at both low and high passage. All cells were
cultured on Transwell at an ALI for 21 days. MDCKII-MDR1 and HEK293 cells were used as MDR1 positive and negative controls respectively. Cells were treated with primary
antibody (A) UIC2 and (B) MRK16. Images are a z-stack of assembled 0.5 lm perpendicular sections of cell layer(s) taken with 63 oil objective and 1 optical zoom with an
average of 4 frames per image. Primary antibodies were labelled with a goat anti-mouse IgG FITC-secondary antibody (green). Nuclear components were counter-stained
with propidium iodide (red). Images are displayed with the apical surface of the cell layers uppermost. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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only 6% of NHBE cells expressed MDR1 (MFI = 1.3). Similar trends
in MDR1 expression levels were obtained with the MRK16 anti-
body with, however, lower ﬂuorescence values recorded, likely
due to a weaker afﬁnity of this antibody for MDR1 (Fig. S1; Supple-
mentary information).3.3. MDR1 functionality
The well-established MDR1 substrate digoxin is often used to
probe MDR1 in biological systems, both in vitro and in vivo
[13,17]. However, the drug has also been reported to be a substrate
for other transporters detected at the gene level in our broncho-
epithelial cell layers (e.g. some of the OATP) [20,21]. Hence, in or-
der to verify the functionality of MDR1 in bronchial epithelial cells,
we performed an UIC2 antibody shift assay in presence of the po-
tent MDR1 inhibitor PSC833 as an alternative to measuring digoxin
efﬂux ratios. This assay is based on the observation that binding of
MDR1 ligands alters the conformation of the transporter, which in-
creases the afﬁnity of the UIC2 antibody for the MDR1 protein and
causes a shift in ﬂuorescence intensity [30,31]. Relative MFI values
of 1.8 and 1.06 were obtained when MDCKII-MDR1or MDCKII-WT
cells, respectively, were pre-incubated with PSC833, in line with
their role as positive and negative controls (Fig. S2; Supplementary
information). Values of 1.27 and 1.26 were calculated for Calu-3
cells at a low or high passage, respectively, while NHBE cells pro-
duced a relative MFI of 1.16 (Fig. S2; Supplementary information),indicating the presence of a MDR1 activity in bronchial epithelial
cells.3.4. 3H-digoxin bidirectional transport
3H-digoxin permeability measurements were performed in
both absorptive (AB) and secretory (BA) directions in MDCKII,
Calu-3 and NHBE cell layers.
Both MDCKII-WT and MDCKII-MDR1 cell layers displayed a net
secretory transport of 3H-digoxin (Fig. 4) which was signiﬁcantly
reduced (p < 0.01) at 4 C (Fig. S3; Supplementary information).
The presence of an apparent efﬂux mechanism in the two cell types
was allegedly ascribed to the activity of the canine mdr1 trans-
porter in MDCKII cells [29]. As predicted, 3H-digoxin efﬂux ratio
was signiﬁcantly higher (p < 0.01) in transfected cells (Fig. 4),
reﬂecting the involvement of the human MDR1 transporter in
3H-digoxin asymmetric transport in the cell line.
A large degree of variability in 3H-digoxin permeability values
was observed between the two batches of NHBE cells employed,
despite originating from the same donor (Fig. 4). Accordingly, a
range of efﬂux ratios between 1.0 and 2.3 were calculated for the
two batches tested under identical culture conditions, questioning
the presence of an efﬂux mechanism for digoxin in NHBE layers.
Although within the acceptable range, 14C-mannitol BA permeabil-
ity values were signiﬁcantly different (p < 0.05) between the two
batches, which might have contributed to the variations in 3H-di-
goxin secretory transport obtained.
Fig. 3. Detection of MDR1 protein expression by ﬂow cytometry in NHBE cell layers and Calu-3 cell layers at high and low passage. All cells were cultured on ﬁlters at an ALI
for 21 days. MDCKII-WT and MDCKII-MDR1 cells were included as negative and positive MDR1 controls, respectively. Data are displayed for 3 x 105 events showing the
secondary control (black) and sample incubated with 0.2 lg/100 ll UIC2 mouse anti-human MDR1 antibody and labelled with 1:1000 goat anti-mouse IgG FITC-tagged
secondary antibody (red). Relative MFI (sample MFI/control MFI) are stated for each cell type. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
Fig. 4. Transport of 25 nM 3H-digoxin across epithelial cell layers in both absorptive
(AB) and secretory (BA) directions. Calu-3 cells and NHBE cell layers were cultured
at an ALI for 21 days and MDCKII cells were cultured for 5 days under submerged
conditions. Data are represented as the mean ± SD of 4 layers.
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and high passage Calu-3 layers, but with a higher efﬂux ratio mea-
sured at a low passage number (Fig. 4). 3H-digoxin asymmetric
transport was abolished at 4 C (Fig. S3; Supplementary informa-
tion), conﬁrming the involvement of a transporter-mediated
mechanism.3.5. Impact of inhibitors on 3H-digoxin bidirectional transport
In order to evaluate the contribution of MDR1 to digoxin
trafﬁcking in MDCKII and Calu-3 layers, inhibition studies were
performed with PSC833 (1 lM), the two speciﬁc MDR1 inhibi-
tory antibodies UIC2 (20 lg/ml) and MRK16 (15 lg/ml) as well
as MK571 (30 lM), an inhibitor of the multidrug resistance
proteins (MRP) [32] which had previously been reported not
to inhibit MDR1 even at a higher concentration of 50 lM
[33]. Considering the poor reproducibility of transport data in
NHBE layers, inhibition studies were not performed in this
model.
Table 2
Impact of inhibitors on 3H-digoxin bidirectional transport.
3H-digoxin Papp (1  106 cm/s)
AB Signiﬁcance BA Signiﬁcance
PSC833 1 lM
MDCKII-WT 1.31 ± 0.18 M 1.25 ± 0.10 ; **
MDCKII-MDR1 0.78 ± 0.03 " ** 3.51 ± 0.21 ; **
Calu-3 Low 2.02 ± 0.22 " ** 2.44 ± 0.10 ; **
Calu-3 High 1.10 ± 0.08 " ** 1.50 ± 0.32 ; **
UIC2 20 lg/ml
MDCKII-WT 0.97 ± 0.16 M 5.56 ± 0.33 M
MDCKII-MDR1 0.52 ± 0.05 " ** 7.43 ± 0.28 ; *
Calu-3 Low 0.20 ± 0.03 ; ** 7.97 ± 1.08 M
Calu-3 High 1.49 ± 0.13 M 4.24 ± 0.32 M
MRK16 15 lg/ml
MDCKII-WT 0.90 ± 0.06 M 5.54 ± 0.05 M
MDCKII-MDR1 0.45 ± 0.03 M 6.88 ± 0.40 ; **
Calu-3 Low 0.63 ± 0.04 M 4.43 ± 0.20 ; *
Calu-3 High 1.58 ± 0.03 M 4.21 ± 0.15 M
MK571 30 lM
MDCKII-WT 2.09 ± 0.12 " ** 7.25 ± 0.65 M
MDCKII-MDR1 1.35 ± 0.02 " ** 7.39 ± 0.53 M
Calu-3 Low 1.61 ± 0.05 " ** 3.70 ± 0.31 ; **
Calu-3 High 1.77 ± 0.14 " ** 2.31 ± 0.07 ; **
Data are presented as mean ± SD (n = 4 layers). M indicate no statistical difference
(p > 0.05) and "; a statistically signiﬁcant increase or decrease compared to per-
meability values obtained in the same experimental conditions in absence of
inhibitors. AB: apical to basolateral; BA: basolateral to apical.
* p < 0.05.
** p < 0.01.
Table 4
Impact of sodium azide (15 mM) on 3H-digoxin bidirectional transport.
3H-digoxin Papp (1  106 cm/s)
AB Signiﬁcance BA Signiﬁcance
MDCKII-WT 1.03 ± 0.09 M 4.92 ± 0.40 M
MDCKII-MDR1 0.52 ± 0.07 " * 5.12 ± 0.20 ; **
Calu-3 Low 0.28 ± 0.02 M 8.03 ± 0.12 M
Calu-3 High 0.86 ± 0.03 M 3.64 ± 0.14 ; *
Data are presented as mean ± SD (n = 4 layers). M indicate no statistical difference
and "; a statistically signiﬁcant increase or decrease compared to permeability
values obtained in the same experimental conditions in absence of sodium azide.
AB: apical to basolateral; BA: basolateral to apical.
* p < 0.05.
** p < 0.01.
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in all cell layers under investigation, reducing or abolishing its
apparent efﬂux (Table 2). This suggested an involvement of
MDR1/mdr1 in the drug transport in both cell lines. Nevertheless,
this was not conﬁrmed by functional inhibitory studies with the
UIC2 and MRK16 antibodies.
Both antibodies are MDR1 speciﬁc probes that react with extra-
cellular loops of the transporter, ﬁxing it in a conformational state
and thus altering the binding of its substrates [30,31]. As antici-
pated, the antibodies had no signiﬁcant impact on 3H-digoxin traf-
ﬁcking in MDCKII-WT cells, but signiﬁcantly decreased 3H-digoxin
BA Papp in MDCKII-MDR1 layers (Table 2). None of the antibodies
affected 3H-digoxin permeability in Calu-3 cells at a high passage
number (Table 2). A small but statistically signiﬁcant decrease in
BA 3H-digoxin transport was observed in Calu-3 layers at a low
passage number with the MRK16 antibody, whereas the UIC2 clone
had no impact on the drug secretory transport in these layers
(Table 2).
MK571 enhanced 3H-digoxin absorptive transport in all cell
types but only reduced the drug secretory permeability in Calu-3
cell layers (Table 2). A relative MFI of 1.05 was obtained in an
UIC2 antibody shift assay performed in MDCKII-MDR1 cells incu-
bated with MK571, conﬁrming the compound does not bind to
MDR1.Table 3
Impact of 3 h incubation in presence of sodium azide (15 mM) on
ATP cellular levels.
% ATP relative to control
MDCKII-WT 17.6 ± 4.0
MDCKII-MDR1 28.8 ± 6.8
calu-3 low 48.6 ± 7.0
Calu-3 high 53.7 ± 5.3
Data are presented as mean ± SD (n = 3 layers).3.6. Impact of ATP depletion on 3H-digoxin bidirectional transport
Since ABC transporters are ATP-dependent, the effect of a reduc-
tion of ATP cellular levels on 3H-digoxin Papp in MDCKII and Calu-3
layers was ﬁnally assessed.
Incubation with 15 mM sodium azide for 3 h induced a 70–
80% and 50% ATP depletion in MDCKII or Calu-3 layers, respec-
tively (Table 3). Interestingly, no signiﬁcant effect of the metabolic
inhibitor on digoxin permeability was observed in MDCKII-WT (Ta-
ble 4), which is in contradiction with a presumed role of the canine
mdr1 in the drug apparent efﬂux in the cell culture model. In con-
trast, decreased ATP production in MDCKII-MDR1 resulted in an
enhanced or reduced digoxin transport in the absorptive or secre-
tory directions, respectively (Table 4). Moreover, in these condi-
tions, BA transport was not signiﬁcantly different (p > 0.05) from
that in the wild type cell layers, suggesting complete inhibition
of the MDR1 transporter. Reduction in ATP levels in Calu-3 layers
did not affect 3H-digoxin apparent efﬂux at a low passage number
but decreased the BA transport by 10% at a higher passage num-
ber (Table 4).4. Discussion
Due to the complexity of the lungs, ALI human bronchial epithe-
lial cell layers are becoming popular systems for investigating
drug-transporter interactions in the airway epithelium [1,7]. How-
ever, the expression and functionality of most transporters have
yet to be meticulously characterised in these models. In particular,
the presence and activity of the MDR1 efﬂux pump in NHBE and
Calu-3 layers remain controversial to date [1]. This may be ex-
plained by inter-laboratory variations in culture conditions but
equally attributed to the use of non-speciﬁc substrates and inhib-
itors in functional studies.
This study characterised MDR1 expression and the bidirectional
transport of the MDR1 probe digoxin in layers of NHBE and the
Calu-3 cell line at low (25–30) or high (45–50) passage numbers
using MDCKII-MDR1 and wild type equivalents for comparison.
MDR1 expression data obtained by three independent protein
detection techniques using three different MDR1 antibodies were
in agreement and indicated a weak presence of the transporter in
NHBE cells as well as an increased expression at a high passage
number in Calu-3 cells (Figs. 1–3). Surprisingly, protein expression
levels in the cell line were in contradiction with the higher ABCB1
transcript levels measured at an early passage number (Table 1).
This highlights the importance of investigating transporter expres-
sion at the protein level in complement to gene proﬁling for a reli-
able appraisal of their presence in the cell culture system under
investigation as well as unbiased interpretation of functional data.
Western blotting revealed a protein band for Calu-3 samples
at a molecular weight 20 kDa lower than for Caco-2 and
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tained a band 150 kDa in Calu-3 cells using the same C219 anti-
body. This clone is known to react with MDR3 (150 kDa) as well
as with MDR1. However, no ABCB4 (MDR3) transcripts were de-
tected in the cell line (Table 1), in agreement with the absence of
this transporter in human airway epithelium samples [35]. More
plausible causes for the presence of a band at a molecular weight
lower than expected could include impaired post-translational
modiﬁcations such as a different degree of glycosylation in Calu-
3 cells. The impact of glycosylation on MDR1functionality is not
completely understood to date with studies having reported either
an uncompromised efﬂux activity [36,37] or conversely, a dimin-
ished function [38,39] of the non-glycosylated transporter. It had
also been postulated that glycosylation was crucial for correct fold-
ing of the MDR1 protein into the cell membrane [40]. However, a
shift assay performed with the conformation sensitive IUC2 anti-
body on Calu-3 cells demonstrated that the efﬂux pump expressed
in the cell line was capable of binding the PSC833 inhibitor and
modifying its conformation following ligand recognition (Fig. S2,
Supplementary info) similarly to a non-glycosylated MDR1 mutant
in presence of the inhibitor cyclosporin A [36]. This indicated that,
despite a possible altered structure, MDR1 was functional in the
Calu-3 cell line.
The 3H-digoxin apparent efﬂux ratio measured in NHBE layers
was poorly reproducible and was therefore not investigated further
(Fig. 4). In Calu-3 layers, this was higher at a low passage (Fig. 4)
whereas MDR1 protein expression levels were greater in cells at
a high passage number (Figs. 1–3). 3H-digoxin transport was not
affected by ATP depletion at low passage and only marginally at
a high passage number (Table 4). Furthermore, the two MDR1 spe-
ciﬁc inhibitory antibodies MRK16 and IUC2 had no impact on the
drug trafﬁcking in high passage Calu-3 layers while the MRK16
clone alone decreased BA transport at a low passage number (Ta-
ble 2). The extent of MDR1 inhibition by MRK16 and UIC2,
although speciﬁc, has been described as partial (10–40%) and lar-
gely dependent on the substrate under investigation [41]. Assum-
ing that the 3H-digoxin permeability in the secretory direction in
MDCKII-MDR1 cells above that in their wild type counterparts is
the component mediated by the transfected human efﬂux pump,
a 20% and 30% reduction in MDR1 mediated digoxin transport
was obtained with the UIC2 and MRK16 antibodies, respectively,
which validated the experimental protocol followed. Finally,
MK571 increased 3H-digoxin absorptive transport in both MDCKII
and Calu-3 layers but only reduced its secretory transport in the
bronchial cell line (Table 2). In contrast, the drug permeability in
the BA direction was decreased in presence of PSC833 in all cell
layers (Table 2). In addition to its inhibitory properties on various
MRP carriers [32], MK571 has been recently reported to interfere
with the activity of OATP1B3 and OATP2B1 at a concentration as
low as 1 lM [42,43]. Its modulatory effects on other OATP trans-
porters present in Calu-3 layers (Table 1) are currently unknown.
Nevertheless, the compound has been shown not to interact with
MDR1 [33], which we conﬁrmed in an IUC2 shift assay. Although
PSC833 was originally developed as a speciﬁc MDR1 inhibitor, it
has since been reported to inhibit other ABC transporters, such as
the bile salt extrusion pump (BSEP) [44], MRP2 [45] or the breast
cancer resistance protein (BCRP, Solvo Biotech website) and its
ability to inhibit OATP transporters has been suggested [46].
Taken together, 3H-digoxin permeability data in Calu-3 layers
do not support an exclusive participation of the MDR1 transporter
in its apparent efﬂux and suggest the involvement of one or several
ATP-independent transport system(s). Similarly, it has previously
been demonstrated that MDR1 was not the sole transporter
responsible for digoxin asymmetric transport in the Caco-2 intesti-
nal absorption model [33] and in MDR1 transfected MDCK cell lay-
ers [47].Although this/these transporter(s) remain(s) to be identiﬁed,
OATP4C1 might be a possible candidate since digoxin is a known
substrate [20,21], the transporter is present in Calu-3 layers and
a lower gene expression was observed at a high passage number
(Table 1). Assuming protein levels are in agreement with those of
mRNA transcripts, this could explain the reduced digoxin apparent
efﬂux in high passage cell layers. This assumption implies a baso-
lateral location of OATP4C1 in Calu-3 layers in line with the baso-
lateral presence of OATP transporters that has been recently
postulated in the airway epithelium of foals [48]. However, there
remains a possibility that digoxin is transported across bronchial
epithelial cell layers by a transporter yet to be characterised, as
suggested in other cell culture models [22,23,47]. For instance, in
addition to the apical MDR1 efﬂux pump, a basolaterally located
uptake transporter was required to account for digoxin net secre-
tory transport in MDCKII-MDR1 cell layers but this transporter
could not be identiﬁed using a panel of inhibitors [47]. As previ-
ously debated for the MDCKII-MDR1 absorption model [47], the
likely involvement of multiple transporters in digoxin bidirectional
transport in Calu-3 layers questions its suitability for probing
MDR1 activity in the bronchial epithelium.5. Conclusions
This study exempliﬁes the complexity of analysing in vitro per-
meability data obtained with substrates of multiple transporters
and highlights the need for thorough characterisation of trans-
porter expression in cell based drug absorption models. The sole
participation of MDR1 in digoxin net secretory transport in Calu-
3 layers could not be demonstrated and the contribution of an
ATP-independent transporter such as a basolaterally located mem-
ber of the OATP family was therefore hypothesised. Identiﬁcation
of this unknown transporter might provide a better understanding
of the distribution of drugs in the pulmonary tissue.
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